Technology

Orgenesis

$6.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-2.24%) Today
$0.00 (0.00%) As of 1:05 PM UTC after-hours

Why Robinhood?

You can buy or sell Orgenesis and other stocks, options, and ETFs commission-free!

About ORGS

Orgenesis Inc. Common Stock, also called Orgenesis, is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD. The listed name for ORGS is Orgenesis Inc. Common Stock.

CEO
Vered Caplan
Employees
309
Headquarters
Germantown, Maryland
Founded
2008
Market Cap
158.69M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
365.78K
High Today
$7.22
Low Today
$6.28
Open Price
$7.00
Volume
233.77K
52 Week High
$8.20
52 Week Low
$2.76

Collections

ORGS Earnings

-$1.26
-$0.69
-$0.13
$0.44
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

TTNP
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure